SuperworthMovado MOV
- Market cap
- $701.9M
- PE
- 17.5×
- 10y median 13.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.0×
- EV/EBIT
- 11.8×
- Revenue, 12 months
- $689.9M
- +5% on a year ago
- Net margin
- 6.0%
- Free cash flow yield
- 10.2%
Movado trades at 17.5× trailing earnings, near its ten-year median. Revenue was $689.9M over the last twelve months, up 5% on a year earlier with a 6% net margin.
Charts
Financials
| Income statement | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $184.1M−13% | $175.8M−10% | $134.4M−8% | $157M−1% | $180.5M−2% | $181.5M+3% | $131.8M−2% | $161.8M+3% | $186.1M+3% | $191.6M+6% | $142.4M+8% | $169.8M+5% | |
| Cost of revenue | $84.3M−7% | $81.7M−4% | $61.5M−4% | $71.7M+2% | $83.9M−0% | $83.1M+2% | $60.4M−2% | $74.3M+4% | $85.1M+1% | $87.9M+6% | $60.8M+1% | $68.9M−7% |
| Gross profit | $99.8M−18% | $94.1M−14% | $72.9M−12% | $85.3M−3% | $96.6M−3% | $98.3M+5% | $71.3M−2% | $87.6M+3% | $101.1M+5% | $103.6M+5% | $81.6M+14% | $100.8M+15% |
| SG&A | $81.6M−1% | $83.3M+0% | $70.8M−0% | $82.6M+4% | $90.6M+11% | $89.1M+7% | $71.1M+0% | $83.6M+1% | $89.3M−1% | $89.8M+1% | $74.6M+5% | $85.9M+3% |
| $18.2M−53% | $10.8M−59% | $2.1M−82% | $2.6M−67% | $6M−67% | $9.2M−15% | $291K−86% | $4M+52% | $11.7M+94% | $13.8M+50% | $7M+2311% | $14.9M+271% | |
| Interest expense | $135K−6% | $136K−16% | $118K+4% | $110K−3% | $144K+7% | $117K−14% | $111K−6% | $110K+0% | $136K−6% | $150K+28% | $102K−8% | $108K−2% |
| Pre-tax income | $19.7M−49% | $12.4M−55% | $4.2M−67% | $4.4M−53% | $7.4M−62% | $10.7M−14% | $1.9M−54% | $5.1M+16% | $12.9M+75% | $14.4M+35% | $8.9M+357% | $16M+214% |
| $4.2M−51% | $2.3M−42% | $2M−23% | $843K−68% | $2.4M−43% | $2.2M−6% | $660K−68% | $2M+133% | $3.3M+39% | $1.6M−28% | $1.9M+195% | $3.5M+80% | |
| Net income | $15.2M−48% | $9.8M−57% | $2M−79% | $3.5M−47% | $4.8M−68% | $8.1M−18% | $1.4M−30% | $3M−14% | $9.6M+99% | $12.6M+56% | $6.9M+388% | $12.3M+312% |
| $0.67−48% | $0.43−57% | $0.09−79% | $0.15−48% | $0.21−69% | $0.36−16% | $0.06−33% | $0.13−13% | $0.42+100% | $0.55+53% | $0.30+400% | $0.53+308% | |
| 22.7M−1% | 22.7M+0% | 22.7M+0% | 22.7M+0% | 22.6M−1% | 22.5M−1% | 22.5M−1% | 22.6M−0% | 22.7M+1% | 23M+2% | 22.8M+2% | 23.1M+2% |
Revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
SG&A: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Operating income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Income tax: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Net income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY11: share-days: the 6-month average less the second quarter's. Q4 FY11 and Q4 FY18: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 13 periods, Q4 FY12 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Movado's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| Peer median | $1.1B | 32.3× | 41.7× | 1.9× | +10% | 6.5% |
More on Movado
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 136Healthcare stocks with the fastest earnings growth
- #4of 45Medical instruments and supplies stocks with the highest free cash flow yield
- #3of 33Medical instruments and supplies stocks with the fastest earnings growth
- #9of 46Medical instruments and supplies stocks with the lowest EV/EBIT
- #8of 35Medical instruments and supplies stocks with the lowest PE ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .